{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:39:49Z","timestamp":1790375989708,"version":"4.1.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,26]]},"abstract":"<jats:p>In this timely Blood Spotlight, Barta et al summarize for the practicing hematologist the strengths and limitations of current data on brentuximab vedotin\u2013based treatment in peripheral T-cell lymphoma (PTCL).<\/jats:p>","DOI":"10.1182\/blood.2019001821","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T15:59:37Z","timestamp":1572019177000},"page":"2339-2345","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Brentuximab vedotin in the treatment of CD30+ PTCL"],"prefix":"10.1182","volume":"134","author":[{"given":"Stefan K.","family":"Barta","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Perelman School of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald Z.","family":"Gong","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Pathology, Thomas Jefferson University, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-023X","authenticated-orcid":false,"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Sidney Kimmel Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2019122611530747900_B1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.25513","article-title":"Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management","volume":"94","author":"Zain","year":"2019","journal-title":"Am J Hematol"},{"issue":"20","key":"2019122611530747900_B2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019122611530747900_B3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2019122611530747900_B4","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1002\/cncr.28676","article-title":"Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network","volume":"120","author":"Herrera","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"2019122611530747900_B5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.clml.2016.10.001","article-title":"Analysis of peripheral T-cell lymphoma diagnostic workup in the United States","volume":"17","author":"Hsi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2019122611530747900_B6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"2019122611530747900_B7","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019122611530747900_B8","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"issue":"11","key":"2019122611530747900_B9","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"issue":"8","key":"2019122611530747900_B10","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00277-019-03694-y","article-title":"First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients","volume":"98","author":"Janikova","year":"2019","journal-title":"Ann Hematol"},{"issue":"6","key":"2019122611530747900_B11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.15258","article-title":"Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network","volume":"181","author":"Federico","year":"2018","journal-title":"Br J Haematol"},{"issue":"36","key":"2019122611530747900_B12","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","article-title":"International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma","volume":"35","author":"Maurer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019122611530747900_B13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-Cell Consortium Trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2019122611530747900_B14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/10428194.2018.1516873","article-title":"A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma","volume":"60","author":"Hapgood","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019122611530747900_B15","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/10428194.2018.1515937","article-title":"A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study","volume":"60","author":"Reiman","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019122611530747900_B16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"issue":"5","key":"2019122611530747900_B17","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","article-title":"CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial","volume":"5","author":"Gleeson","year":"2018","journal-title":"Lancet Haematol"},{"issue":"9","key":"2019122611530747900_B18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","article-title":"NCCN guidelines insights: non-Hodgkin\u2019s lymphomas, Version 3.2016","volume":"14","author":"Horwitz","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2019122611530747900_B19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.hoc.2016.11.003","article-title":"Autologous and allogeneic hematopoietic cell transplantation in peripheral T\/NK-cell lymphomas: a histology-specific review","volume":"31","author":"Dhawale","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"2019122611530747900_B20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study [published correction appears in Cancer. 2019;125(21):3893]","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"issue":"6","key":"2019122611530747900_B21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.clml.2017.05.001","article-title":"Treatment of peripheral T-cell lymphoma in community settings","volume":"17","author":"Feldman","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2019122611530747900_B22","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-018-3288-7","article-title":"The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience","volume":"97","author":"Rohlfing","year":"2018","journal-title":"Ann Hematol"},{"issue":"3","key":"2019122611530747900_B23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"issue":"25","key":"2019122611530747900_B24","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019122611530747900_B25","doi-asserted-by":"crossref","first-page":"djw248","DOI":"10.1093\/jnci\/djw248","article-title":"T-cell lymphoma: recent advances in characterization and new opportunities for treatment","volume":"109","author":"Casulo","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2019122611530747900_B26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ijc.2910280406","article-title":"Hodgkin and Sternberg-Reed cell antigen(s) detected by an antiserum to a cell line (L428) derived from Hodgkin\u2019s disease","volume":"28","author":"Stein","year":"1981","journal-title":"Int J Cancer"},{"issue":"5878","key":"2019122611530747900_B27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/299065a0","article-title":"Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin\u2019s disease and a subset of normal lymphoid cells","volume":"299","author":"Schwab","year":"1982","journal-title":"Nature"},{"issue":"3","key":"2019122611530747900_B28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","article-title":"Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin\u2019s disease","volume":"68","author":"D\u00fcrkop","year":"1992","journal-title":"Cell"},{"issue":"1","key":"2019122611530747900_B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2013.10.007","article-title":"First Hodgkin cell line L428 and the CD30 antigen: their role for diagnostic and treatment of CD30-positive neoplasms","volume":"28","author":"Stein","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"2019122611530747900_B30","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.bloodjournal664848","article-title":"The expression of the Hodgkin\u2019s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells","volume":"66","author":"Stein","year":"1985","journal-title":"Blood"},{"issue":"4","key":"2019122611530747900_B31","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.3390\/cancers10040107","article-title":"The pathological spectrum of systemic anaplastic large cell lymphoma (ALCL)","volume":"10","author":"Montes-Mojarro","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2019122611530747900_B32","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"2019122611530747900_B33","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/PAS.0b013e31822067d1","article-title":"Nonhepatosplenic \u03b3\u03b4 T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation","volume":"35","author":"Garcia-Herrera","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2019122611530747900_B34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/PAS.0b013e31824433d8","article-title":"Extranodal NK\/T-cell lymphoma, nasal type, includes cases of natural killer cell and \u03b1\u03b2, \u03b3\u03b4, and \u03b1\u03b2\/\u03b3\u03b4 T-cell origin: a comprehensive clinicopathologic and phenotypic study","volume":"36","author":"Pongpruttipan","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"2019122611530747900_B35","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1097\/DAD.0000000000000560","article-title":"Neurotropic gamma-delta T-cell lymphoma with CD30-positive lymphoid infiltrates","volume":"38","author":"Gammon","year":"2016","journal-title":"Am J Dermatopathol"},{"issue":"19","key":"2019122611530747900_B36","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019122611530747900_B37","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","article-title":"CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features","volume":"98","author":"Bisig","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"2019122611530747900_B38","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.clml.2015.11.013","article-title":"A single-center experience with brentuximab vedotin in gamma delta T-cell lymphoma","volume":"16","author":"Talpur","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2019122611530747900_B39","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/PAS.0000000000001041","article-title":"The use of central pathology review with digital slide scanning in advanced-stage mycosis fungoides andS\u00e9zary syndrome: a multi-institutional and international pathology study","volume":"42","author":"Gru","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"32","key":"2019122611530747900_B40","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019122611530747900_B41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/cco.2018.12.03","article-title":"The spectrum of CD30+ T cell lymphoproliferative disorders in the skin","volume":"8","author":"Kartan","year":"2019","journal-title":"Chin Clin Oncol"},{"issue":"19","key":"2019122611530747900_B42","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019122611530747900_B43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Forero-Torres","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"2019122611530747900_B44","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy [published corrections appears in Nat Biotechnol. 2003;21:941]","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2019122611530747900_B45","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"issue":"19","key":"2019122611530747900_B46","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"18","key":"2019122611530747900_B47","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019122611530747900_B48","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2019122611530747900_B49","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"28","key":"2019122611530747900_B50","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019122611530747900_B51","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"issue":"10168","key":"2019122611530747900_B52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"18","key":"2019122611530747900_B53","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"32","key":"2019122611530747900_B54","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"32","key":"2019122611530747900_B55","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10094","key":"2019122611530747900_B56","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"suppl 15","key":"2019122611530747900_B57","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1200\/JCO.2019.37.15_suppl.7543","article-title":"Response to brentuximab vedotin by CD30 expression: results from five trials in PTCL, CTCL, and B-cell lymphomas","volume":"37","author":"Jagadeesh","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019122611530747900_B58","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial","volume":"129","author":"Zinzani","year":"2017","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/26\/2339\/1549667\/bloodbld2019001821c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/26\/2339\/1549667\/bloodbld2019001821c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T22:38:12Z","timestamp":1611614292000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/26\/2339\/422645\/Brentuximab-vedotin-in-the-treatment-of-CD30-PTCL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,26]]},"references-count":58,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2019,12,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001821","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,26]]}}}